Bruker (BRKR) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChartTranscripts

BRKR Stock Forecast


Bruker stock forecast is as follows: an average price target of $73.75 (represents a 24.26% upside from BRKR’s last price of $59.35) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.

BRKR Price Target


The average price target for Bruker (BRKR) is $73.75 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $80.00 to $60.00. This represents a potential 24.26% upside from BRKR's last price of $59.35.

BRKR Analyst Ratings


Buy

According to 7 Wall Street analysts, Bruker's rating consensus is 'Buy'. The analyst rating breakdown for BRKR stock is 0 'Strong Buy' (0.00%), 6 'Buy' (85.71%), 1 'Hold' (14.29%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Bruker Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 23, 2024Patrick DonnellyCitigroup$80.00$67.5418.45%34.79%
Aug 27, 2024Brandon CouillardWells Fargo$78.00$63.9521.97%31.42%
May 20, 2024Daniel AriasStifel Nicolaus$77.00$76.470.69%29.74%
May 05, 2021Tycho PetersonJ.P. Morgan$60.00$68.86-12.87%1.10%
Row per page
Go to

The latest Bruker stock forecast, released on Sep 23, 2024 by Patrick Donnelly from Citigroup, set a price target of $80.00, which represents a 18.45% increase from the stock price at the time of the forecast ($67.54), and a 34.79% increase from BRKR last price ($59.35).

Bruker Price Target by Period


1M3M12M
# Anlaysts-23
Avg Price Target-$79.00$78.33
Last Closing Price$59.35$59.35$59.35
Upside/Downside-100.00%33.11%31.98%

In the current month, the average price target of Bruker stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Bruker's last price of $59.35. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Oct 15, 2024Barclays-OverweightInitialise
Sep 30, 2024Wolfe Research-Peer PerformDowngrade
Sep 23, 2024CitigroupBuyBuyHold
Aug 28, 2024Wells FargoOverweightPositiveInitialise
Aug 27, 2024Wells Fargo-OverweightInitialise
Aug 07, 2024Cowen & Co.HoldHoldHold
Jul 10, 2024CitigroupBuyBuyHold
May 20, 2024CitigroupBuyBuyHold
May 20, 2024Bank of America SecuritiesBuyBuyHold
Feb 15, 2024UBSBuyBuyHold
Row per page
Go to

Bruker's last stock rating was published by Barclays on Oct 15, 2024. The company Initialise its BRKR rating from "null" to "Overweight".

Bruker Financial Forecast


Bruker Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
Revenue------------$854.50M$742.80M$681.90M$685.30M$708.40M$638.90M$588.40M$595.00M$683.50M$608.90M$570.80M$554.70M$627.50M$511.40M$424.60M$424.00M$599.90M$521.10M
Avg Forecast$1.16B$1.01B$934.80M$884.80M$1.07B$928.90M$876.46M$843.59M$1.01B$866.46M$799.47M$729.88M$807.45M$714.61M$647.82M$639.76M$680.10M$609.98M$588.22M$572.58M$661.93M$575.19M$537.10M$513.06M$603.36M$484.92M$391.49M$443.92M$576.91M$494.16M
High Forecast$1.16B$1.01B$934.80M$884.80M$1.07B$928.90M$876.46M$843.59M$1.01B$881.14M$799.47M$729.88M$807.66M$727.78M$647.82M$639.76M$680.10M$609.98M$588.22M$572.58M$661.93M$575.19M$537.10M$513.06M$603.36M$484.92M$391.49M$443.92M$576.91M$494.16M
Low Forecast$1.16B$1.01B$934.80M$884.80M$1.07B$928.90M$876.46M$843.59M$1.01B$856.81M$799.47M$729.88M$807.22M$703.69M$647.82M$639.76M$680.10M$609.98M$588.22M$572.58M$661.93M$575.19M$537.10M$513.06M$603.36M$484.92M$391.49M$443.92M$576.91M$494.16M
# Analysts545443435851285443435454516811711
Surprise %------------1.06%1.04%1.05%1.07%1.04%1.05%1.00%1.04%1.03%1.06%1.06%1.08%1.04%1.05%1.08%0.96%1.04%1.05%

Bruker's average Quarter revenue forecast for Mar 24 based on 1 analysts is $729.88M, with a low forecast of $729.88M, and a high forecast of $729.88M. BRKR's average Quarter revenue forecast represents a -14.58% decrease compared to the company's last Quarter revenue of $854.50M (Dec 23).

Bruker EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts545443435851285443435454516811711
EBITDA------------$144.90M$160.50M$117.50M$153.10M$161.40M$155.30M$108.00M$125.70M$143.90M$137.20M$114.60M$115.80M$147.40M$104.80M$56.80M$36.00M$136.90M$99.60M
Avg Forecast$230.00M$201.26M$186.09M$176.14M$213.42M$184.91M$174.48M$167.93M$201.70M$172.48M$159.15M$130.69M$160.74M$142.26M$128.96M$118.80M$162.91M$121.43M$117.10M$93.92M$131.77M$114.50M$106.92M$66.56M$120.11M$96.53M$77.93M$47.72M$114.84M$98.37M
High Forecast$230.00M$201.26M$186.09M$176.14M$213.42M$184.91M$174.48M$167.93M$201.70M$175.41M$159.15M$156.82M$160.78M$144.88M$128.96M$142.57M$195.49M$121.43M$117.10M$112.70M$131.77M$114.50M$106.92M$79.88M$120.11M$96.53M$77.93M$57.27M$114.84M$98.37M
Low Forecast$230.00M$201.26M$186.09M$176.14M$213.42M$184.91M$174.48M$167.93M$201.70M$170.56M$159.15M$104.55M$160.69M$140.08M$128.96M$95.04M$130.33M$121.43M$117.10M$75.13M$131.77M$114.50M$106.92M$53.25M$120.11M$96.53M$77.93M$38.18M$114.84M$98.37M
Surprise %------------0.90%1.13%0.91%1.29%0.99%1.28%0.92%1.34%1.09%1.20%1.07%1.74%1.23%1.09%0.73%0.75%1.19%1.01%

1 analysts predict BRKR's average Quarter EBITDA for Mar 24 to be $130.69M, with a high of $156.82M and a low of $104.55M. This is -9.81% lower than Bruker's previous annual EBITDA (Dec 23) of $144.90M.

Bruker Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts545443435851285443435454516811711
Net Income------------$205.50M$88.10M$57.10M$76.50M$97.40M$88.10M$49.50M$61.60M$76.00M$87.10M$57.60M$56.70M$68.90M$54.30M$24.10M$10.50M$68.60M$61.30M
Avg Forecast$177.60M$148.00M$118.40M$100.64M$154.74M$110.12M$93.55M$84.18M$138.51M$88.97M$75.97M$71.43M$101.12M$93.69M$72.05M$64.94M$83.27M$81.82M$66.84M$51.33M$86.59M$65.49M$56.29M$35.44M$83.14M$46.54M$8.50M$14.61M$87.28M$55.96M
High Forecast$177.60M$148.00M$118.40M$100.64M$154.74M$110.12M$93.55M$84.18M$138.51M$96.27M$75.99M$85.72M$105.79M$96.67M$72.05M$77.92M$99.92M$81.82M$66.84M$61.60M$86.59M$65.49M$56.29M$42.52M$83.14M$46.54M$8.50M$17.53M$87.28M$55.96M
Low Forecast$177.60M$148.00M$118.40M$100.64M$154.74M$110.12M$93.55M$84.18M$138.51M$84.60M$75.95M$57.14M$96.45M$92.20M$72.05M$51.95M$66.62M$81.82M$66.84M$41.07M$86.59M$65.49M$56.29M$28.35M$83.14M$46.54M$8.50M$11.69M$87.28M$55.96M
Surprise %------------2.03%0.94%0.79%1.18%1.17%1.08%0.74%1.20%0.88%1.33%1.02%1.60%0.83%1.17%2.83%0.72%0.79%1.10%

Bruker's average Quarter net income forecast for Mar 24 is $71.43M, with a range of $57.14M to $85.72M. BRKR's average Quarter net income forecast represents a -65.24% decrease compared to the company's last Quarter net income of $205.50M (Dec 23).

Bruker SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts545443435851285443435454516811711
SG&A------------$205.20M$177.60M$177.90M$162.70M$164.70M$144.80M$152.20M$145.70M$156.50M$141.40M$134.70M$131.90M$132.90M$114.90M$104.30M$125.60M$133.10M$125.90M
Avg Forecast$276.20M$241.68M$223.47M$211.52M$256.29M$222.06M$209.52M$201.66M$242.21M$207.13M$191.12M$169.42M$193.02M$170.83M$154.86M$154.01M$168.63M$145.82M$140.62M$121.75M$158.24M$137.50M$128.40M$82.44M$144.24M$115.92M$93.59M$176.00M$137.91M$118.13M
High Forecast$276.20M$241.68M$223.47M$211.52M$256.29M$222.06M$209.52M$201.66M$242.21M$210.64M$191.12M$203.30M$193.07M$173.98M$154.86M$184.82M$202.36M$145.82M$140.62M$146.10M$158.24M$137.50M$128.40M$98.92M$144.24M$115.92M$93.59M$211.20M$137.91M$118.13M
Low Forecast$276.20M$241.68M$223.47M$211.52M$256.29M$222.06M$209.52M$201.66M$242.21M$204.82M$191.12M$135.53M$192.97M$168.22M$154.86M$123.21M$134.90M$145.82M$140.62M$97.40M$158.24M$137.50M$128.40M$65.95M$144.24M$115.92M$93.59M$140.80M$137.91M$118.13M
Surprise %------------1.06%1.04%1.15%1.06%0.98%0.99%1.08%1.20%0.99%1.03%1.05%1.60%0.92%0.99%1.11%0.71%0.97%1.07%

Bruker's average Quarter SG&A projection for Mar 24 is $169.42M, based on 1 Wall Street analysts, with a range of $135.53M to $203.30M. The forecast indicates a -17.44% fall compared to BRKR last annual SG&A of $205.20M (Dec 23).

Bruker EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts545443435851285443435454516811711
EPS------------$1.41$0.60$0.39$0.52$0.66$0.60$0.33$0.41$0.50$0.58$0.38$0.37$0.45$0.35$0.16$0.07$0.45$0.40
Avg Forecast$1.20$1.00$0.80$0.68$1.05$0.74$0.63$0.57$0.94$0.60$0.51$0.47$0.68$0.63$0.49$0.55$0.72$0.55$0.45$0.42$0.59$0.44$0.38$0.33$0.56$0.31$0.06$0.23$0.59$0.38
High Forecast$1.20$1.00$0.80$0.68$1.05$0.74$0.63$0.57$0.94$0.65$0.51$0.47$0.71$0.65$0.49$0.55$0.72$0.55$0.45$0.42$0.59$0.44$0.38$0.33$0.56$0.31$0.06$0.23$0.59$0.38
Low Forecast$1.20$1.00$0.80$0.68$1.05$0.74$0.63$0.57$0.94$0.57$0.51$0.47$0.65$0.62$0.49$0.55$0.72$0.55$0.45$0.42$0.59$0.44$0.38$0.33$0.56$0.31$0.06$0.23$0.59$0.38
Surprise %------------2.06%0.95%0.80%0.95%0.91%1.09%0.73%0.98%0.85%1.31%1.00%1.13%0.80%1.11%2.78%0.31%0.76%1.06%

According to 1 Wall Street analysts, Bruker's projected average Quarter EPS for Mar 24 is $0.47, with a low estimate of $0.47 and a high estimate of $0.47. This represents a -67.01% decrease compared to BRKR previous annual EPS of $1.41 (Dec 23).

Bruker Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
FNAParagon 28$6.06$11.5089.77%Buy
OFIXOrthofix Medical$17.33$31.0078.88%-
LUNGPulmonx$7.12$11.9367.56%Buy
IRTCiRhythm$81.44$121.1748.78%Buy
LIVNLivaNova$49.01$70.5043.85%Buy
KIDSOrthoPediatrics$28.74$39.6037.79%Buy
CNMDCONMED$70.47$96.0036.23%Buy
BIOBio-Rad Laboratories$368.92$482.5030.79%Buy
BRKRBruker$59.35$73.7524.26%Buy
ZBHZimmer Biomet$108.41$133.5723.21%Hold
AORTArtivion$27.46$30.6011.43%Buy
ITGRInteger$126.53$138.009.07%Buy
SRDXSurmodics$37.57$39.505.14%Buy
GKOSGlaukos$131.38$119.33-9.17%Buy

BRKR Forecast FAQ


Yes, according to 7 Wall Street analysts, Bruker (BRKR) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 85.71% of BRKR's total ratings.

Bruker (BRKR) average price target is $73.75 with a range of $60 to $80, implying a 24.26% from its last price of $59.35. The data is based on 7 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

According to Wall Street analysts' prediction for BRKR stock, the company can go up by 24.26% (from the last price of $59.35 to the average price target of $73.75), up by 34.79% based on the highest stock price target, and up by 1.10% based on the lowest stock price target.

BRKR's average twelve months analyst stock price target of $73.75 does not support the claim that Bruker can reach $90 in the near future.

Bruker's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $3.72B (high $3.72B, low $3.72B), average EBITDA is $740.74M (high $740.74M, low $740.74M), average net income is $442.58M (high $442.58M, low $442.58M), average SG&A $889.54M (high $889.54M, low $889.54M), and average EPS is $2.99 (high $2.99, low $2.99). BRKR's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $3.99B (high $3.99B, low $3.99B), average EBITDA is $793.49M (high $793.49M, low $793.49M), average net income is $544.64M (high $544.64M, low $544.64M), average SG&A $952.87M (high $952.87M, low $952.87M), and average EPS is $3.68 (high $3.68, low $3.68).

Based on Bruker's last annual report (Dec 2023), the company's revenue was $2.96B, beating the average analysts forecast of $2.81B by 5.51%. Apple's EBITDA was $557.8M, beating the average prediction of $550.76M by 1.28%. The company's net income was $427.2M, beating the average estimation of $331.8M by 28.75%. Apple's SG&A was $706.9M, beating the average forecast of $672.73M by 5.08%. Lastly, the company's EPS was $2.9, beating the average prediction of $2.35 by 23.29%. In terms of the last quarterly report (Dec 2023), Bruker's revenue was $854.5M, beating the average analysts' forecast of $807.45M by 5.83%. The company's EBITDA was $144.9M, missing the average prediction of $160.74M by -9.85%. Bruker's net income was $205.5M, beating the average estimation of $101.12M by 103.22%. The company's SG&A was $205.2M, beating the average forecast of $193.02M by 6.31%. Lastly, the company's EPS was $1.41, beating the average prediction of $0.683 by 106.37%